77%).
Data on OS are immature and not significant (HR, 0.70; 95% CI, 0.47â€“1.05).
Patients receiving T-DM1 were more likely to discontinue treatment because of an adverse event (18% vs.
2.1%) and had a higher frequency of sensory neuropathy (18.6% vs.
6.9%), most cases of which had resolved at the time of the analysis.
On subgroup analysis, the benefit of T-DM1 was observed in all subgroups, including participants who received dual HER2-targeted therapy in the preoperative setting.
Neratinib is an irreversible tyrosine kinase inhibitor of HER1, HER2, and HER4, which has been approved by the FDA for the extended adjuvant treatment of patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.